Next Article in Journal
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
Previous Article in Journal
A Novel Application of Buprenorphine Transdermal Patch to Relieve Pain in the Knee Joint of Knee Osteoarthritis Patients: A Retrospective Case-Control Study
Open AccessArticle

Associations of Plasma 3-Methylhistidine with Frailty Status in French Cohorts of the FRAILOMIC Initiative

1
Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), 14558 Nuthetal, Germany
2
NutriAct-Competence Cluster Nutrition Research Berlin-Potsdam, 14558 Nuthetal, Germany
3
Institute of Nutritional Sciences, University of Hohenheim, 70599 Stuttgart, Germany
4
Inserm, Bordeaux Population Health Research Center, UMR 1219, University Bordeaux, 33000 Bordeaux, France
5
Center for Molecular Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
6
Division of Geriatrics, Hospital Universitario de Getafe, 28905 Getafe, Spain
7
German Center for Diabetes Research (DZD), 85764 Munich-Neuherberg, Germany
8
German Center for Cardiovascular Research (DZHK), 13347 Berlin, Germany
*
Author to whom correspondence should be addressed.
On behalf of the FRAILOMIC initiative.
J. Clin. Med. 2019, 8(7), 1010; https://doi.org/10.3390/jcm8071010
Received: 12 June 2019 / Revised: 5 July 2019 / Accepted: 8 July 2019 / Published: 10 July 2019
(This article belongs to the Section Epidemiology & Public Health)
Frailty and sarcopenia are characterized by a loss of muscle mass and functionality and are diagnosed mainly by functional tests and imaging parameters. However, more muscle specific biomarkers are needed to improve frailty diagnosis. Plasma 3-methylhistidine (3-MH), as well as the 3-MH-to-creatinine (3-MH/Crea) and 3-MH-to-estimated glomerular filtration rate (3-MH/eGFR) ratios might support the diagnosis of frailty. Therefore, we investigated the cross-sectional associations between plasma 3-MH, 3-MH/Crea and 3-MH/eGFR with the frailty status of community-dwelling individuals (>65 years). 360 participants from two French cohorts of the FRAILOMIC initiative were classified into robust, pre-frail and frail according to Fried’s frailty criteria. General linear models as well as bivariate and multiple linear and logistic regression models, which were adjusted for several confounders, were applied to determine associations between biomarkers and frailty status. The present study consisted of 37.8% robust, 43.1% pre-frail and 19.2% frail participants. Frail participants had significantly higher plasma 3-MH, 3-MH/Crea and 3-MH/eGFR ratios than robust individuals, and these biomarkers were positively associated with frailty status. Additionally, the likelihood to be frail was significantly higher for every increase in 3-MH (1.31-fold) and 3-MH/GFR (1.35-fold) quintile after adjusting for confounders. We conclude that 3-MH, 3-MH/Crea and 3-MH/eGFR in plasma might be potential biomarkers to identify frail individuals or those at higher risk to be frail, and we assume that there might be biomarker thresholds to identify these individuals. However, further, especially longitudinal studies are needed. View Full-Text
Keywords: frailty; aging; methylhistidine; biomarker; human study; muscle protein turnover frailty; aging; methylhistidine; biomarker; human study; muscle protein turnover
MDPI and ACS Style

Kochlik, B.; Stuetz, W.; Pérès, K.; Féart, C.; Tegner, J.; Rodriguez-Mañas, L.; Grune, T.; Weber, D. Associations of Plasma 3-Methylhistidine with Frailty Status in French Cohorts of the FRAILOMIC Initiative. J. Clin. Med. 2019, 8, 1010.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop